MC2 Biotek, a clinical stage specialty pharmaceutical company focused on the development and commercialization of topical drugs that addresses the major problem of non-compliance of otherwise highly efficacious and safe topical therapies, announced today that one poster will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle from May 1-5, 2016.

“The data we are going to present at ARVO illustrate the key features of our PAD™ Technology. Our interactions with ophthalmologists have confirmed that there is a crucial need for a well tolerated and effective ciclosporin drug, which does not contain quaternary ammoniums such as BAK or CKC. Through 2015 we completed, all the steps for our clinical study, which, today, is open in Europe, with first patients having been recruited and treated for 3 months”, commented Jesper J. Lange, President of MC2 Biotek.

Wednesday, May 4, 3:45 – 5:30 PM, session 475 (Inflammation)
“Pharmacokinetic characterization of a novel ocular formulation of ciclosporin”
Praestegaard Morten, Steele Fraser, Gomez Frédéric

BACK